Menu
← Oncology Approval Tracker
FDA DECISION ·
Trodelvy
sacituzumab govitecan-hziy · Immunomedics / Gilead
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
Patients with unresectable locally advanced or metastatic triple-negative breast cancer after at least two prior systemic regimens, including at least one for metastatic disease.
LAMPGEN ANALYSIS
Why it matters
This converts accelerated approval of a Trop-2-directed antibody-drug conjugate and specifies the prior-line requirement.
What research teams should watch
Separate adjuvant and metastatic therapy history and follow neutropenia, diarrhea and dose changes.
PRIMARY RECORDS